Back to results

Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

Primary Purpose

Malaria, Plasmodium Falciparum

Status

Completed

Phase

Phase 1

Locations

Netherlands

Study Type

Interventional

Intervention

PfSPZ Challenge

Normal Saline (NS)

About this trial

This is an interventional prevention trial for Malaria focused on measuring Malaria, Plasmodium falciparum, PfSPZ Challenge, Chemoprophylaxis, PfSPZ-CVac

Eligibility Criteria

18 Years - 35 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Healthy volunteers (males or females) of ≥ 18 and ≤ 35 years of age
Good health based on history and clinical examination (physical examination and laboratory screening)
Negative pregnancy test
Use of adequate contraception for females
Signing of the informed consent form, thereby demonstrating understanding of the meaning and procedures of the study
Agreement to inform the general practitioner and to sign a request to release medical information concerning contraindications for participation in the study
Willingness to undergo administration of PfSPZ Challenge by needle and syringe and willingness to undergo challenge by mosquito bites
For volunteers not living in Nijmegen: agreement to stay in a hotel room close to the trial centre or living in Nijmegen with a third party that could contact the clinicians in case of alteration of consciousness during a part of the study (day 5 after challenge until treatment is finished)
Reachable (24/7) by mobile phone during the whole study period
For volunteers living in Nijmegen: living with a third party that could contact the clinicians in case of alteration of consciousness or agreement to stay in a hotel room close to the trial centre during a part of the study (day 5 after challenge until treatment is finished)
Available to attend all study visits
Agreement to refrain from blood donation to Sanquin or for other purposes, during the whole study period
Willingness to undergo HIV, hepatitis B and hepatitis C tests
Negative urine toxicology screening test at screening visit and the day before challenge
Willingness to take a prophylactic regime of chloroquine and a curative regimen of Malarone®
Willingness to undergo ophthalmologic examination after passing all other inclusion criteria

Exclusion Criteria:

History of malaria
Plans to travel to malaria endemic areas during the study period
Plans to travel outside of the Netherlands during the challenge period
Previous participation in any malaria vaccine study and/or positive serology for Pf
Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers
History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)
History of arrhythmias or prolonged QT-interval
Positive family history of 1st and/or 2nd degree relatives who experienced cardiac events when < 50 years old
An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system
Clinically significant abnormalities in electrocardiogram (ECG) at screening
Body Mass Index (BMI) below 18 or above 30 kg/m2
Any clinically significant deviation from the normal range in biochemistry or haematology blood tests
Positive HIV, HBV or HCV tests
Participation in any other clinical study within 30 days prior to the onset of the study
Enrolment in any other clinical study during the study period
For women: pregnancy or lactation
Volunteers unable to give written informed consent
Volunteers unable to be closely followed for social, geographic or psychological reasons
History of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrolment in the study
A history of psychiatric disease
A history of convulsions
Known hypersensitivity to Malarone® or chloroquine
The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months of study onset (inhaled and topical corticosteroids are allowed) and during the study period
Contraindications to Malarone® or chloroquine including treatment taken by the volunteer that interferes with Malarone® or chloroquine
Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia
Co-workers or trainees of the departments of Medical Microbiology or Internal Medicine of the RUNMC
Known history of sickle cell anaemia, sickle cell trait, thalassemia, thalassemia trait or G6PD deficiency. If there is any suspicion of G6PD deficiency (based on medical history during screening or ethnic background -Mediterranean, African, or Asian), we will assess G6PD status of that particular subject before inclusion.
Abnormalities during ophthalmologic examination

Sites / Locations

Radboud University Nijmegen Medical Centre

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

Grp 1: 75,000 PfSPZ Challenge, 3 immunizations

Grp 2: Normal Saline (NS)

Grp 3: 75,000 PfSPZ Challenge, 3/4 immunizations

Grp 4: Normal Saline (NS)

Arm Description

Grp 1 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 1 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 & 64 (immunizations 1, 2 & 3). 33 days after last dose of CQ, Grp 1 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.

Grp 2 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 2 gets ID injections of normal saline, on days 8, 36 & 64 (immunizations 1, 2 & 3). 33 days after last dose of CQ, Grp 2 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.

Grp 3 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 3 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 & 64 (immunizations 1, 2 & 3). Grp 3 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If <75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will receive 1 additional immunization (immunization 4), consisting of 6 ID injections on the same day of 75,000 PfSPZ Challenge, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 3 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.

Grp 4 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 wks(98 days). In this time, Grp 4 gets ID injections of NS, on days 8, 36 & 64 (immunizations 1, 2 & 3). Grp 4 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If <75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will receive 1 additional immunization (immunization 4), consisting of ID injections of NS, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 4 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.

Outcomes

Primary Outcome Measures

Frequency and magnitude of adverse events in study groups

Signs and symptoms will be recorded at all visits, and whenever a trial volunteer reports signs or symptoms to the trial physician between visits. The following signs and symptoms will be solicited: Fever, Headache, Malaise, Fatigue, Dizziness, Myalgia, Arthralgia, Nausea, Vomiting, Chills, Diarrhoea, Abdominal pain (Verhage 2005), Chest pain, Palpitations and Shortness of breath.

Secondary Outcome Measures

Presence of parasitemia after Pf CHMI as assessed by microscopy

Thick smear samples will be taken from a 3 ml EDTA vacutainer tube. Thick smears will be performed on all visits following immunizations and Pf CHMI until treatment is finished. Thick smears will be performed according to a standard operating procedure, which is based on an internationally harmonized protocol for thick smears in CHMIs (Moorthy et al., WHO). In short, 15μl of whole blood will be distributed on standardized 3-well slides, providing an equal slide thickness for all smears. Slides are dried and stained with Giemsa. Per slide, 200 fields will be read, which correlates to 0.5 µl of blood. Slides are considered positive if they contain 2 or more parasites per 200 fields. Thick smears evaluation will take place at the RUNMC.

Time to parasitemia after Pf CHMI as assessed by microscopy

Kinetics of parasitemia as assessed by qPCR

Samples for qPCR will be collected from the same 3 ml EDTA vacutainer tubes as the thick smear sample. qPCR will be performed according to standard procedure described in Hermsen et al. Mol, Biochem. Parasitol. 2001; 118: 247-251. In short, qPCR will be performed on the multicopy 18S ribosomal RNA gene. All samples are spiked with murine white blood cells and a murine albumin gene PCR is used to determine efficacy of DNA isolation. Samples for quantitative measurement of parasitemia will be prepared and stored at RUNMC. Measurement by qPCR will be performed retrospectively.

Full Information

NCT ID

NCT01728701

First Posted

November 6, 2012

Last Updated

May 12, 2017

Sponsor

Sanaria Inc.

Collaborators

Radboud University Medical Center

1. Study Identification

Unique Protocol Identification Number

NCT01728701

Brief Title

Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

Official Title

Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

Study Type

Interventional

2. Study Status

Record Verification Date

May 2014

Overall Recruitment Status

Completed

Study Start Date

September 2012 (undefined)

Primary Completion Date

December 2013 (Actual)

Study Completion Date

February 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Sanaria Inc.

Collaborators

Radboud University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The purpose of the study is to determine the safety and tolerability of ID administration of PfSPZ Challenge to volunteers taking chloroquine chemoprophylaxis (an approach called PfSPZ-CVac).

Detailed Description

The study is a single centre, double blind, randomized controlled clinical trial. Volunteers, investigators and laboratory personnel will be blinded. A maximum of 30 volunteers will be randomly divided into four groups. All volunteers will receive standard weekly chloroquine chemoprophylaxis for a period of 14 weeks (98 days). During this period, groups 1 and 3 will receive six ID injections of PfSPZ Challenge, containing a total of 75,000 PfSPZ of the Pf NF54 strain, on days 8, 36 and 64 (immunizations 1, 2 and 3). The control groups 2 and 4 will receive ID injections with normal saline (NS) on the same days. Thirty-three days after the last dose of chloroquine, volunteers in groups 1 and 2 will have controlled human malaria infection (CHMI) by the bites of five mosquitoes infected with PfSPZ of the Pf NF54 strain. If ≥75% of volunteers in group 1 are protected against this homologous Pf CHMI, volunteers in groups 3 and 4 will have CHMI by the bites of five mosquitoes infected with the heterologous Pf NF135.C10 strain 75 days after the last dose of chloroquine. If <75% of volunteers in group 1 are protected against the homologous Pf CHMI, volunteers in groups 3 and 4 will receive an additional immunization (immunization 4), which will consist of six ID injections on the same day of 75,000 PfSPZ Challenge and NS respectively, at day 162. In this fourth immunization period chloroquine will be administered for another 6 weeks starting at day 154. Finally, 33 days after the last dose of chloroquine, volunteers in groups 3 and 4 will have homologous Pf CHMI by the bites of five PfSPZ-infected mosquitoes. After CHMI all volunteers will be treated with a curative regimen of Malarone® (each tablet containing 250 mg atovaquone and 100 mg proguanil), either at the time of detection of blood stage parasitemia or 21 days after exposure to PfSPZ-infected mosquitoes. Volunteers will be checked for parasites by thick smear at least twice after treatment. If one of the volunteers is not fit to participate in the study on day -1, an alternate volunteer who passed screening will replace him or her. For this purpose 3 additional volunteers will be screened for possible back up.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Malaria, Plasmodium Falciparum

Keywords

Malaria, Plasmodium falciparum, PfSPZ Challenge, Chemoprophylaxis, PfSPZ-CVac

7. Study Design

Primary Purpose

Prevention

Study Phase

Phase 1

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

30 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Grp 1: 75,000 PfSPZ Challenge, 3 immunizations

Arm Type

Experimental

Arm Description

Arm Title

Grp 2: Normal Saline (NS)

Arm Type

Placebo Comparator

Arm Description

Arm Title

Grp 3: 75,000 PfSPZ Challenge, 3/4 immunizations

Arm Type

Experimental

Arm Description

Arm Title

Grp 4: Normal Saline (NS)

Arm Type

Placebo Comparator

Arm Description

Intervention Type

Biological

Intervention Name(s)

PfSPZ Challenge

Intervention Description

PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.

Intervention Type

Biological

Intervention Name(s)

Normal Saline (NS)

Intervention Description

Normal saline

Primary Outcome Measure Information:

Title

Frequency and magnitude of adverse events in study groups

Description

Time Frame

All study visits+as reported by volunteer upto 53 weeks

Secondary Outcome Measure Information:

Title

Presence of parasitemia after Pf CHMI as assessed by microscopy

Description

Time Frame

Thick smears will be performed on all visits following immunizations and Pf CHMI until treatment is finished upto 53 weeks

Title

Time to parasitemia after Pf CHMI as assessed by microscopy

Description

Time Frame

Thick smears will be performed on all visits following immunizations and Pf CHMI until treatment is finished upto 53 weeks

Title

Kinetics of parasitemia as assessed by qPCR

Description

Time Frame

Samples collected on all visits following immunizations and Pf CHMI until treatment is finished upto 53 weeks

Other Pre-specified Outcome Measures:

Title

Immune responses in study groups: Cellular immune responses, Antibody production, Cytokine profile

Description

The overall objective is to find immunological markers or signatures that associate with protective efficacy at immune RNA profile or cell response level. Immunogenicity assays will be performed on samples from both vaccinees and infectivity controls from baseline and throughout the period of study. Humoral assessment will include antibody assays by immunofluorescence, ELISAs for specific Pf proteins and serological activity with a proteome chip representing thousands of Pf proteins. In addition antibody functionality will be tested in a series of sporozoite inhibition assays. Cellular assessment of parasite-specific (subset)T cell responses, will be conducted by multi-parameter flow cytometry and ELISPOT assays) using Pf-specific in vitro stimulation by a number of antigens.

Time Frame

Baseline and throughout the period of study upto 53 weeks

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

35 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Healthy volunteers (males or females) of ≥ 18 and ≤ 35 years of age Good health based on history and clinical examination (physical examination and laboratory screening) Negative pregnancy test Use of adequate contraception for females Signing of the informed consent form, thereby demonstrating understanding of the meaning and procedures of the study Agreement to inform the general practitioner and to sign a request to release medical information concerning contraindications for participation in the study Willingness to undergo administration of PfSPZ Challenge by needle and syringe and willingness to undergo challenge by mosquito bites For volunteers not living in Nijmegen: agreement to stay in a hotel room close to the trial centre or living in Nijmegen with a third party that could contact the clinicians in case of alteration of consciousness during a part of the study (day 5 after challenge until treatment is finished) Reachable (24/7) by mobile phone during the whole study period For volunteers living in Nijmegen: living with a third party that could contact the clinicians in case of alteration of consciousness or agreement to stay in a hotel room close to the trial centre during a part of the study (day 5 after challenge until treatment is finished) Available to attend all study visits Agreement to refrain from blood donation to Sanquin or for other purposes, during the whole study period Willingness to undergo HIV, hepatitis B and hepatitis C tests Negative urine toxicology screening test at screening visit and the day before challenge Willingness to take a prophylactic regime of chloroquine and a curative regimen of Malarone® Willingness to undergo ophthalmologic examination after passing all other inclusion criteria Exclusion Criteria: History of malaria Plans to travel to malaria endemic areas during the study period Plans to travel outside of the Netherlands during the challenge period Previous participation in any malaria vaccine study and/or positive serology for Pf Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers History of diabetes mellitus or cancer (except basal cell carcinoma of the skin) History of arrhythmias or prolonged QT-interval Positive family history of 1st and/or 2nd degree relatives who experienced cardiac events when < 50 years old An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system Clinically significant abnormalities in electrocardiogram (ECG) at screening Body Mass Index (BMI) below 18 or above 30 kg/m2 Any clinically significant deviation from the normal range in biochemistry or haematology blood tests Positive HIV, HBV or HCV tests Participation in any other clinical study within 30 days prior to the onset of the study Enrolment in any other clinical study during the study period For women: pregnancy or lactation Volunteers unable to give written informed consent Volunteers unable to be closely followed for social, geographic or psychological reasons History of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrolment in the study A history of psychiatric disease A history of convulsions Known hypersensitivity to Malarone® or chloroquine The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months of study onset (inhaled and topical corticosteroids are allowed) and during the study period Contraindications to Malarone® or chloroquine including treatment taken by the volunteer that interferes with Malarone® or chloroquine Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia Co-workers or trainees of the departments of Medical Microbiology or Internal Medicine of the RUNMC Known history of sickle cell anaemia, sickle cell trait, thalassemia, thalassemia trait or G6PD deficiency. If there is any suspicion of G6PD deficiency (based on medical history during screening or ethnic background -Mediterranean, African, or Asian), we will assess G6PD status of that particular subject before inclusion. Abnormalities during ophthalmologic examination

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Robert Sauerwein, MD

Organizational Affiliation

Radboud University Medical Center

Official's Role

Principal Investigator

Facility Information:

Facility Name

Radboud University Nijmegen Medical Centre

City

Nijmegen

ZIP/Postal Code

6500 HB

Country

Netherlands

12. IPD Sharing Statement

Learn more about this trial

Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

We'll reach out to this number within 24 hrs